Related Experiment Video
Updated: Jun 11, 2026

Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System
Published on: July 11, 2025
A Real-Time Mobile AI-Assisted System for Skin Disease Prescreening: A Technical Feasibility Study
Utshob Sutradhar1, Priyankar Biswas1, Tapos Chandra Saha1
1Department of Electrical and Electronic Engineering Gopalganj Science and Technology University Gopalganj Bangladesh.
Background And Aims:
Skin diseases remain a widespread health concern, particularly in areas where access to dermatological care is limited. With the growing availability of smartphones and advances in deep learning, mobile-based image analysis offers a practical option for early-stage screening. This study aims to develop and evaluate a lightweight, real-time mobile AI-assisted system for skin disease prescreening on Android devices.
Methods:
An Android application, SkinLearn, was developed by integrating a YOLO11-based image classification model optimized for on-device inference using TensorFlow Lite. The model was trained on a publicly available seven-class skin disease dataset and further evaluated on the PAD-UFES-20 skin cancer dataset to examine its ability to generalize across datasets. A YOLOv8 model was also implemented under the same conditions for comparison.
Results:
The proposed YOLO11 model achieved a top-1 accuracy of 99.2% on the seven-class dataset and 71.4% on the PAD-UFES-20 dataset, outperforming the YOLOv8 baseline in both cases. The mobile implementation enabled real-time, offline inference with low computational overhead, demonstrating efficient deployment in resource-constrained environments. However, the observed performance drop across datasets highlights challenges related to domain shift, class imbalance, and variability in imaging conditions.
Conclusion:
These findings support the technical feasibility of lightweight deep learning models such as YOLO11 for accessible mobile skin disease prescreening. However, the observed performance drop on PAD-UFES-20 indicates that further validation across more diverse datasets and clinical settings is needed before any real-world clinical use is considered.
